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Phage therapy has a long tradition in Eastern Europe, where preparations are comprised of complex
phage cocktails whose compositions have not been described. We investigated the composition of a
phage cocktail from the Russian pharmaceutical company Microgen targeting Escherichia coli/Proteus
infections. Electron microscopy identiﬁed six phage types, with numerically T7-like phages dominating
over T4-like phages. A metagenomic approach using taxonomical classiﬁcation, reference mapping and
de novo assembly identiﬁed 18 distinct phage types, including 7 genera of Podoviridae, 2 established and
2 proposed genera of Myoviridae, and 2 genera of Siphoviridae. De novo assembly yielded 7 contigs
greater than 30 kb, including a 147-kb Myovirus genome and a 42-kb genome of a potentially new phage.
Bioinformatic analysis did not reveal undesired genes and a small human volunteer trial did not associate
adverse effects with oral phage exposure.
& 2013 Elsevier Inc. All rights reserved.Introduction
The World Health Organization has ofﬁcially announced an
antibiotic crisis. The crisis has two aspects: on one side there are
an ever increasing number of important human bacterial patho-
gens becoming resistant to antibiotics, and on the other side there
are less and less new antibiotics developed by the pharmaceutical
industry. Alternatives to antibiotics are thus urgently needed
(WHO, 2012). A potentially promising treatment and prevention
mode is bacteriophage therapy (Brüssow et al., 2012; Merabishvili
et al., 2009; Rhoads et al., 2009; Smith and Huggins, 1982;
Sulakvelidze et al., 2001; Wright et al., 2009). Bacteriophages are
viruses infecting bacteria and, due to their lytic activity on theirll rights reserved.
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esearch Centre, East Street,host cells, phages have already been explored as therapeutic
agents by Félix d'Herelle, who discovered phage nearly a century
ago at the Pasteur Institute in Paris. With a Georgian collaborator,
Eliava, he went to the Soviet Union, where he founded a large
applied phage institute in Tbilisi. The Eliava Institute became the
cradle of Soviet phage therapy and, during its heydays, provided
therapeutic phages at an industrial scale to the Red Army (Häusler,
2007). With the disintegration of the Soviet Union, the tradition of
the Eliava Institute was taken up by Russian pharmaceutical
companies, which currently provide the public sector with over-
the-counter phage products sold in pharmacies as a registered
product. The Russian company Microgen sells phages as liquid
preparations or as pressed pills for a number of infections (http://
eng.microgen.ru/catalog/). However, no detailed scientiﬁc reports
describe their safe use in healthy subjects, let alone their safety
and efﬁcacy in patients (Sulakvelidze et al., 2001; Sulakvelidze and
Kutter, 2005; Brüssow, 2005). Not even the composition of these
Russian phage preparations has been described in scientiﬁc
reports. Here we investigated the Microgen ColiProteus phage
preparation against E. coli/Proteus infection independently from
any information about the cocktail composition from the supplier.
Metagenomic analysis is becoming increasingly frequently
employed for the investigation of viral populations in both
environmental and clinical samples (Breitbart et al. 2002; Ng et
al., 2011; Pride et al., 2012; Reyes et al., 2010, 2012; Tse et al., 2012;
S. McCallin et al. / Virology 443 (2013) 187–196188Willner et al., 2009; Victoria et al., 2009). A common strategy to
characterize such data sets involves de novo assembly of contigs
directly from sequencing reads, followed by extensive homology
searches. However, closely related species within a sample can
create difﬁculties when using this methodology, and the choice of
appropriate assembler programs and alignment parameters is
important (Teeling and Glöckner, 2012; Breitbart et al., 2002).
Here we analyzed sequencing data ﬁrst by taxonomical classiﬁca-
tion of reads using the MetaGenomic ANalyser (MEGAN) (Huson
and Mitra, 2012) and reference mapping. These two assembly-
independent methods were followed by a de novo assembly of
unmapped reads to identify potentially new phage genomes. We
then used bioinformatic methods to establish the genetic safety of
this phage cocktail (Brüssow et al., 2004; Brüssow 2010) and
demonstrated their biological safety in a small human
volunteer trial.Results
Electron microscopy
We concentrated phages by a combination of medium and
high-speed centrifugation steps directly from the commercial
phage preparation. Next to small membrane debris from lysed
bacteria, these preparations showed two main constituents: Myo-
viruses with prolate heads that morphologically resembled T4-like
phages and Podoviruses resembling T7-like phages, which were
numerically the most prominent phage in the cocktail (Fig. 1A).
With lower numbers, we also observed tailed phages with
isometric capsids of different diameters and distinct tail and
baseplates structures (Fig. 1B–G).
MetaGenomic sequencing and taxonomic classiﬁcation
The workﬂow for the analysis of the DNA sequences from the
Microgen ColiProteus cocktail is described in Fig. 2. In a ﬁrst step, aFig. 1. Negative stain electron microscopy of bacteriophages directly concentrated from
membranous debris representing a typical view of the sample. (B–G): Gallery of phages
differed morphologically. For example, phages from panel B and F differ in baseplate st
structure. Panel G shows phages with contracted tails from an undeﬁned Myovirus. The pcrude virus pellet was isolated from the Microgen cocktail by
differential centrifugation and the total viral DNA was extracted
and sequenced with the Illumina HiSeq 2000 technology, yielding
16.4 million paired-end reads of 100 bp. After ﬁltering for low
quality and low complexity sequences, 3.2% of reads were
removed. When removing redundancy at 100% identity, the read
set decreased to 3.6 million non-redundant (nr) paired-end reads.
This nr set was used for safety evaluation and reference mapping.
To permit time-consuming blastx analysis, we then removed
redundancy at 95% identity to locate divergent reads. This further
reduced the set to 0.6 million reads. These reads were compared
against the NCBI-NR protein database.
All blastx ﬁles were then imported into MEGAN, which assigns
hits to taxa using the Lowest Common Ancestor (LCA) algorithm,
in order to visualize the taxonomic content of the reads (Huson
and Mitra, 2012). Reads were classiﬁed in MEGAN as Myoviridae
(34%), Podoviridae (24%), Siphoviridae (6%), unclassiﬁed phage
(1%), and as “bacterial” DNA (10%), while 23% showed no hits
(Fig. 3A).
Reference mapping
Reference genomes closely related to phages contained in the
cocktail were identiﬁed by increasing the stringency parameters in
MEGAN (Supplementary Fig. 1). Of the 14 reference genomes
identiﬁed by MEGAN, 11 were mapped along the majority of their
genome with a high depth of coverage with the nr read set,
demonstrating that similar phages were part of the Microgen
cocktail. Microgen phages included three genera of the Myoviridae
family: the genus Tevenvirinae with a 170-kb genome size (repre-
sented with the subgroups of T4-, RB69- and RB49, but not JS98-
like phages Suppl. Fig. 2A and B), Felixounalikevirus (the broad
host range Salmonella phage Felix O1 (Villegas et al., 2009;
Whichard et al., 2010) with a 86-kb genome) (Whichard et al.,
2010) (Suppl. Fig. 2E), and the newly proposed genus of rv5-like
Myoviridae with a 140-kb genome (Santos et al., 2011; Schwarzer
et al., 2012) (Suppl. Fig. 2D). Microgen phages also included threethe Microgen phage cocktail. (A): T4-like Myoviridae, T7-like Podoviridae, and
which were identiﬁed after searching the samples for less abundant viruses, which
ructure, phages from panel C differ in head size, phages from panel D and E in tail
anels are not with the same magniﬁcation, size estimates are provided by the scales.
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Fig. 2. Metagenomic workﬂow. During a ﬁrst step, phages were sterile-ﬁltered and concentrated by differential centrifugation to isolate phages. The phage pellet was then
treated with DNase to remove free DNA not encapsulated into virions. Phage DNA was then extracted with phenol/chloroform and used for sequencing with Illumina
technology. Then, the paired-end 100 bp reads were cleared from low quality and ambiguous sequences prior to the creation of read sets to be used for the later steps of
analysis. Blastx searches of the 95% nr list were opened in MEGAN for taxonomic classiﬁcation and identiﬁcation of reference genomes to be mapped with the 100% nr read
set. Reads not mapped to reference genomes were used for de novo assembly. Separately, the entire 100% nr read set was screened against the DUG database. Reference
genomes and de novo assembled putative phage genomes, as well as DUG hits, were mapped again with the full read set to determine their relative abundance of phage DNA
in the cocktail.
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graphivirinae we identiﬁed the T7likevirus genus (with closest
relatives to T7, K1F, and MmP1 phages, Suppl. Fig. 3A–C) (Scholl
and Merril, 2005; Zhu et al., 2010) and SP6likevirus genus (closest
relative K1-5, Suppl. Fig. 3D) (Bull et al., 2010; Scholl et al., 2002,
2004) both in the 40-kb genome size range. The third Podovirus
genus in the Microgen cocktail was N4likevirus (closest relative
phage vB_EcoP_G7C, Suppl. Fig. 3E), which has a 73 kb genome
with terminal repeats (Kulikov et al., 2012). A taxonomically still
unclassiﬁed K1-ind(1)-like phage from the Siphoviridae family
with a 46 kb genome was also part of the Microgen cocktail (Suppl.
Fig. 4). The projection of the sequence reads on these reference
genomes showed differences in depth of coverage (e.g. T74T4).
Small regions of no coverage were visible in many of these
alignments in elements expected to show diversity, such as in
the tail ﬁber region, endonuclease genes, and genes for hypothe-
tical proteins. (Comeau et al., 2007; Miller et al., 2003; Tétart et al.,
1998) Conﬂicts in the mappings represent the sequence variability
of closely-related phages and indicate that each mapping was
representative of several phages. (e.g. compare the left and right
genome segments of T7, Suppl. Fig. 3A).
Bacterial DNA
Almost all “bacterial” matches in MEGAN showed upon
manual re-investigation best hits to T7-like phages from E. coli.The few remaining “bacterial” hits were with putative prophage
or mobile DNA elements from E. coli, Shigella, and Proteus
integrated into bacterial chromosomes (matching integrases,
transposases, helicases, portal proteins, terminase, or phage tail
genes). The lack of sequence alignment of the nr reads with the
reference genomes of E. coli NC_000913 and Proteus mirabilis
AM942759, the assumed ampliﬁcation strains for cocktail
production, further conﬁrmed that the phage fraction of the
cocktail did not contain bacterial DNA. Exceptions were the E.
coli gene yﬁD involved in anaerobic glycolysis carried by a T4-
like phage (Brüssow 2010; Sarker et al., 2012) and a Proteus
gene annotated as a phage recombination protein (data not
shown).
De novo assembly
Collectively, 61% of nr Microgen reads aligned with Caudo-
virales. No reads were shared between Myoviridae, Podovir-
idae, or Siphoviridae mappings. All reads attributed to the
reference genomes identiﬁed in the MEGAN analysis at the set
threshold were then removed from the nr set. This left us with
38% of nr reads, which were then used for de novo assembly
(Fig. 3B).
From the set of the unattributed reads, 97% assembled into
1121 contigs, 508 which were larger than 500 bp length (Fig. 3B).
Blastn searches revealed that 30 contigs had no hits in the
T4-like
Felix01
rv5-like
phAPEC8-like
T7-like
K1F-like
MmP1-like
vB_EcoP_G7C-like
K1-5-like
CUS-3-like
phiV10-like
K1ind1
RTP-like
ColProt1
ColProt2
5.E+03
1.E+06
2.E+06
3.E+06
4.E+06
5.E+06
6.E+06
7.E+06
0 20000 40000 60000 80000 100000 120000 140000 160000 180000
R
ea
ds
 a
ttr
ib
ut
ed
 (n
)
Genome length (bp)
T4-like
Felix01
rv5-like
phAPEC8-like
T7-like
K1F-like
MmP1-like
vB_EcoP_G7C-like
K1-5-like
CUS-3-like
phiV10-like
K1ind1
RTP-like
ColProt1
ColProt2
Fig. 3. Statistics of Microgen phage cocktail sequence attribution. (A). Proportion of best blastx match for 95% nr reads classiﬁed by MEGAN as Caudovirales (Myoviridae, Podoviridae,
or Siphoviridae classiﬁed separately in the right expansion), “bacteria,” unclassiﬁed phage, unassigned, or no hit. “Bacterial” hits were on manual re-analysis of phage origin (see
Results), hence the quotationmarks. Unassigned classiﬁcation indicates that a hit was found for the read, but did not exceed the minimal threshold criteria for classiﬁcation (default
parameters). (B). Proportion of 100% nr reads attributed through reference mapping to known genomes (Myoviridae, Podoviridae, or Siphoviridae, right expansion), to de novo
assembled contigs (separated by size of contigs, left expansion), or that remained unattributed. (C). Distribution of full reads to phages identiﬁed by reference mapping or de novo
assembly (de novo contigs are indicated in italics). The size of the circles is proportional to the average coverage in reads of the genome. The circles are placed according to the
genome size of the respective phage groups given on the abscissa and according to sequence abundance given on the ordinate in a logarithmic scale.
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Fig. 4. Selected de novo assembled contigs are aligned with related phage genomes. Genome alignment of phAPEC8-like contig (A), the Rtp-like contig (B), and the phiV10-like
contig (C) with their respective reference genomes. DNA sequence comparison is visualized with the Artemis Comparison Tool (ACT) and ORFs of the reference genomes are
indicated by arrows. Homologous regions correspond to minimum blastn score of 100 and 80% identity. The shading gives a grading for the identity level of the aligned
genome segments. (D). Regions of homology of a 40-kb contig with reference genomes CUS-3 (black), lambda (white), and HK140 (grey).
S. McCallin et al. / Virology 443 (2013) 187–196190databases, while the remaining contigs had their best hits with
phages from the Caudovirales order. The assembly also resulted in
seven contigs greater than 30 kbp (Fig. 3B, Suppl. Fig. 5).The largest of these contigs measured 147 kbp and it shared
homology along 93% of its genome with the recently published
phage phAPEC8, with an average nucleotide percent identity of
S. McCallin et al. / Virology 443 (2013) 187–196 19198%. Alignment gaps were over a tail ﬁber protein, a putative
dTDP-glucose 4,6-dehydratase, and several hypothetical proteins
(Fig. 4A). Phage phAPEC8 is a distant relative of the rv5-like
Myovirus group (Tsonos et al., 2012) and was not yet present in
the public databases at the time of our initial analysis and was
thus not detected for reference mapping.
A contig of 51 kbp shared 69% of homology with phage Rtp
(Fig. 4B), an unclassiﬁed member of the Tunalikevirus genus in the
Siphoviridae family (Wietzorrek et al., 2006) whose 46-kb genome
shares organization, but not sequence identity with E. coli phage
T1. Comparison of the Rtp reference phage with this contig
showed no or only partial homology for numerous hypothetical
proteins, two endonuclease genes, a DNA primase, tail ﬁber, and a
tail tape measure protein.
A contig of 39 kb shared similarity with the epsilon15-like
Podovirus phiV10 over 63% of its genome length covering virion,
lysis, lysogeny and replication genes (Perry et al., 2009) (Fig. 4C). This
contig also aligned across 83% of its length with an unidentiﬁed
prophage from E. coli strain IHE3034 (Accession number: CP001969).
A contig of 40 kb shared sequence identity over different
regions with three temperate phages (Fig. 4D); namely the P22-
like Podovirus CUS-3 (King et al., 2007) (over 47% of the contig
length covering DNA replication, lysis and virion genes), phage
lambda (integrase, antirepressor and CII protein) and phage HK140
(several hypothetical proteins).
Finally, two contigs of 40 and 42.5 kb length showed few
matches. The ﬁrst of which, ColProt1, shared protein sequence
identity with phage DNA packaging and injection proteins, and the
latter, ColProt2, shared only weak protein sequence identity over a
quarter of its length with phage LIMElight (capsid, RNA polymerase,
DNA polymerase) and phage KP3 (DNA maturase, DNA exonuclease).
Abundance of different phages in the cocktail
Through reference mapping and de novo assembly with the nr
reads from the Microgen cocktail, we were able to identify the
presence of 17 different groups of phages. However, it was necessary
to analyze the full set of reads in order to gain insight into their
relative proportions within the Microgen cocktail (anticipating no PCR
ampliﬁcation bias). This analysis identiﬁed T7-like phages as the most
abundant ingredient of the Microgen phage cocktail, followed by T4-
like phages, which was consistent with the EM observations. Nine
further phage groups made important contributions to the cocktail
that clustered, with the exception of two 140 kb- and one 70 kb-
long phages, around a genome size of 40 kb. Astonishing was the
contribution of ColProt2: despite the fact that it showed no homology
over 75% of its length it represents after T7-like phages, one of the
most important contributors to the ColiProteus cocktail (Fig. 3C).
Undesired genes
We screened the Microgen reads against our in-house Data-
base of Undesired Genes (DUG) (Zuber et al., 2007). Two relevant
DUG matches were identiﬁed: one was to a gene conferring a
greater environmental ﬁtness to E. coli with respect to acid
resistance (dps gene; Choi et al., 2000) and the other gene
encoded a serum resistance factor (lambda bor-like gene
(Barondess and Beckwith, 1995) from DLP12 prophage of the
non-pathogenic Escherichia fergusonii).
Safety trial of Microgen phages in human volunteers
In a small safety trial we gave Microgen phages to ﬁve healthy
adults as well as ﬁve, 5 to 10-year old children, and ﬁve children
below 5 years of age, all from Bangladesh. The subjects received
the phage at a high dose, at a ten-fold lower dose and placebo.Each subject received all three treatments in a random order and
thus served as his/her own control allowing for the detection of
adverse effects with a small group of exposed volunteers.
The adults showed normal body–mass indices between 22 and
25, while children showed weight for age values in the mild
sub-normal range (75 to 90%). These subjects received Microgen
phages and placebo in random order. The subjects were followed
by weekly complete physical examinations, which did not indicate
problems (Table 1). Clinical chemistry analysis gave values outside
of the normal range for serum creatinine and total serum proteins
in adults and bilirubin mostly in children. Increased aspartate
aminotransferase levels were observed in children younger than
5ys-old (Table 1). Hematology was mostly normal, however,
eosinophils were elevated in 5 to 10 years-old children. Laboratory
values outside the normal range were not more frequently
observed when children were on high titer Microgen phage, as
assessed by fecal phage count, than when on low phage regime
and placebo (15 vs. 39 events); frequently these abnormal values
were already observed in the subjects at the admission to the trial
before any phage product was given (Table 1). Three adult subjects
complained about transient abdominal pain, dyspepsia and tooth-
ache, respectively. One of the older children reported ear pain,
which was treated with antibiotics, while another reported an
episode of cold. One of the younger children showed loose stool.
None of these adverse events was associated with high dose phage
application. No urtical rash or allergy was observed. No phage was
detected in the blood stream nor was a serum antibody increase to
phage seen in the study subjects (data not shown).
Fecal microbiota changes
Larger amounts of stool material were available for four adult
volunteers to allow detailed stool microbiota analysis. The PCR
products of bacterial 16S rDNA from the stool of the adult subjects
were analyzed by denaturing gradient gel electrophoresis (DGGE)
before and after application of the Microgen cocktail (Fig. 5A). Pair
wise calculations using the Dice's similarity scores showed that
proﬁles from the same subject were on average Dsc¼86.8% similar
over the three-week observation period. Visual inspection of the
gels showed that the intensity of the bands varied over the
observation period, suggestive of quantitative changes in fecal
microbiota composition. This observation was conﬁrmed by high
throughput sequencing of PCR-ampliﬁed bacterial 16 S rDNA on
serial stool samples of the adult volunteers (Fig. 5B). However, no
consistent change in microbiota composition was seen in adult
volunteers receiving the high phage dose when feces were three
times sampled over a one-week observation period. Indeed,
substantial changes in microbiota composition were observed in
stool samples collected just two days apart. This short term
variability in fecal microbiota composition was not induced by
phage treatment since a similar variability in fecal microbiota
composition was observed in adult volunteers when on placebo
and sampled in an identical way (Fig. 5B).Discussion
The Soviet phage therapy tradition has risen on one side hope,
if not overt hype, for its potential as an alternative to antibiotics
and on the other side skepticism, if not frank dismissal, as
Stalinistic cure (Stone, 2002). Until the late 1930s Soviet phage
therapy efforts were reported in the Russian literature in detailed
publications much the same as those published in Western
countries. The Second World War and the subsequent Cold War
changed the situation, so that very few data were published on
phage therapy and those that were published were extremely
Table 1
Characteristics of study subjects and observation of abnormal values in physical examination and clinical chemistry or hematology analyses in ﬁfteen healthy volunteers
from Bangladesh of different ages receiving Microgen phage cocktails and placebo.
Subject 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Normal range
Characteristics of subjects:
Age (y) 32 26 40 25 25 9.8 7.4 7.3 9.9 5.4 4.3 3.5 4.5 4 4.3
Sex (1¼m) 1 1 1 1 1 2 2 2 1 2 2 1 2 1 2
Weight (kg) 60 62 65 59 71 27 21 15 24 15 12 14 13 14 13
BMI (1–5), Weight per age 23 24 25 23 24 85 91 64(1) 77 81 75 81 79 82 80
Weight loss40.7 kg – – – – – – – – – – – – – – – o0.7 kg (1.5%)
Pulse rate – – – – – – a3 – (1) – – 3 3 – – 60–100/min
Respiration rate – – – – 1 – – – – – – – a(2) a(2) – 20–30/min
Fever 2 – – – – – – – 3 – – a3 – – – o37.5 1C
Systolic blood pressure – 2 – – a – – – a – – – – – a 110–140
Diastolic blood pressure – – – – – – – – a – – – – – – 60–85
Clinical chemistry:
Na+ – – – – – – – 1 – – – – – a123 – 136–145 mEq/L
K+ – – – – – – – – – – – – – – – 3.5–5.1 mEq/L
Cl- – – – – – – – 1 – – – a – – – 98–107 mEq/L
Total CO2 – 2 – – – – – – – – – 2 – a – 23–29 mEq/L
Ca2+ – – – – – – – – – – – – – – – 2.1–2.6 mmol/L
Creatinine – – a1 a123 123 – – – – – a – – – – 20–100 μmol/L
Blood urea nitrogen – – – – – – – – – – – – – – – 6–20 mg/dL
Total serum protein a123 a2 – a2 – – – – – – – – – – 6.0–8.3 g/dL
Albumin – – – – – – – – – – – – – – – 3.4–5.4 g/dL
Total cholesterol a2 a – – – – – – – – – – o5.18 mmol/L
Triglycerides – – a – a 1 – – 1 2 – 13 a12 – – o1.7 mmol/L
Total bilirubin – a – – – 2 a2 a1 2 a a a12 a a12 5.1–17 mmol/L
Alanine Aminotransferase – 2 – – – – – – – – – – – – – o56 U/L
Aspartate Aminotransferase – – – – – – – – – – a123 2 2 a123 a o40 U/L
γ-GlutamylAminotransferase – – 2 – – – – – – – – – – – – o40 U/L
Fasting blood glucose – – 3 – – – – – – – – – – – – 3.9–5.6 mmol/L
Hematology:
Platelet count – – – – – – – – 2 2 – – a 3 – 170–500,000/μL
Red blood cell count – – – – – – – – 1 – – – – – – 4.3–6.2106/μL
Mean corpuscular volume 3 – 1 – – – – a123 – – a123 a13 82–102 fL
Mean Corp. hemoglobin Conc. – – – – – – – – – – – – – – – 31–35 g/dL
Hemoglobin 3 3 – – – – a13 a123 – – 12 1 2 a23 1 11–16 g/dL
Hematocrit – – – – – a a13 a13 – a123 2 a12 1 34–40%
White blood cell count – – – – – – – – – – – – – – A12 3.9–11109/L
Neutrophils – – – – – – – – 13 – – a123 – a – 45–74% WBC
Lymphocytes – – – – – – – – – a – a123 – a3 – 25–45% WBC
Monocytes a a a3 3 – – – – a – – 2 – 1 – 3–7% WBC
Eosinophils a123 – – – – a123 a123 a13 3 a12 23 a13 – – – 1–7% WBC
Adverse events 1(3) 1(4) 3 3(5) 2(6) 3(7) – – – – 1(8) – – –
The ﬁrst four rows give the physical characteristics (age in years, sex, weight in kg, and nutritional state as body-mass-index for adults and weight-for-age for children) of the
15 study subjects (columns 1–5: adults; 6–10: 5 to 10 y-old; 11–15: o5 y-old children).
The next rows note individually for each subject if abnormal measurements were made during the physical examination, clinical chemistry or hematology analysis. “–”means
that the volunteers showed only values that were within the normal range as deﬁned with respect to the normal reference values given for children in the last column (for
adults, the reference values given in Sarker et al. (2012) were used). Abnormal measurements were noted with “a, 1, 2 or 3” if they were observed at admission or after the
ﬁrst, second or third week of treatment. The abnormal value is underlined and given in bold when the volunteer received during that week the high titer Microgen phage
preparation as assessed by fecal phage titration. Many normal subjects who were judged healthy for the local standard had “abnormal” values already at baseline, e.g. high
eosinophil counts, which might reﬂect high exposure to parasites.
The next rows give in a similar way observation of clinical chemistry values and hematology values which are outside of the normal range.
Notes: (1) this child suffered from second degree malnutrition, (2) these children showed elevated respiration rates of 36/min, but chest examination was normal. Adverse
events: (3): abdominal discomfort; (4): dyspepsia; (5): toothache; (6): ear pain; (7): antibiotics; (8): loose stool.
S. McCallin et al. / Virology 443 (2013) 187–196192short. A large randomized double-blinded, placebo-controlled
prevention trial of diarrheal diseases involving 30,000 children
in the 1960s was, for example, published in a paper comprising 75
text lines and one table (Brüssow, 2005; Sulakvelidze et al., 2001).
The Eliava Institute in Tbilisi has started to compile and publish old
reports, but much material seems to be irretrievably lost (Brüssow,
2012).
Independent of these considerations, diverse phage cocktails
against a wide range of infectious diseases are a registered
medicine in Russia and sold in Russian pharmacies. The specter
of a widening antibiotic resistance for human bacterial infections
makes the exploration of phage therapy an important public
health issue. Here we studied the phage composition of a widely
sold phage product in Russia using two relatively rapid methods of
characterization: electron microscopy and metagenome analysis.
Biological approaches (such as isolation and characterization ofphages) are time consuming and will underestimate the diversity
as long as one does not know the production strains. Electron
microscopy is quickly done and gives a relatively unbiased over-
view, and we could identify in the ColiProteus phage cocktail six
distinct morphotypes, representing all three major groups of tailed
phages. Due to their characteristic morphology, T4-like Myoviridae
and T7-like Podoviridae were easily identiﬁed. EM however is
not very sensitive, and only relatively abundant phages can be
observed, and the relatively restricted morphological diversity of
bacteriophages limits their classiﬁcation. Metagenomics served as
a broadening method to deepen our analysis of the cocktail
composition.
Metagenome analysis has been widely used in environmental
microbiology, mostly with respect to bacteria, but now also
increasingly with respect to viruses (Reyes et al., 2012). This
technique is also appropriate to characterize the viral composition
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Fig. 5. Fecal microbiota changes after phage application. (A). DGGE proﬁles obtained with universal primers HDA1-GC and HDA2 targeting the variable 3 (V3) region of the 16
S rRNA gene in bacteria from the stool of 5 adults from Bangladesh at baseline (B, before receiving oral phages) and after receiving sequentially Microgen phages at high and
lower dose and placebo, each for 2 days and separated by 5 days of wash out at the end of the 3-week follow-up (A, after receiving phages). (B). Bacterial community
structure proﬁles for fecal samples from 4 adult volunteers receiving the Microgen phage cocktail (right) compared to 5 adult volunteers receiving placebo (left). The proﬁles
are given for stool samples taken at days 1, 3, and 8 after oral phage consumption (right half of panel) or placebo (left half of panel) as speciﬁed on the x-axis. The serial stool
samples of each individual subject are grouped next to each other and are separated from the next subject by a vertical bar. The panel gives the proportion of 16 S rRNA (in
percent on the y-axis) ampliﬁed with universal primers targeting the variable 4 (V4) region of the bacterial 16S rRNA gene at the family level. The sequences attributed to a
speciﬁc family are depicted in different colors, the color code is given at the right side. Only the eleven most prominent bacterial families are given, further minor families are
lumped together as “other families”. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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cannot or does not want to provide its composition. Metagenomic
analysis of the ColiProteus cocktail increased the number of
different phage types that could be differentiated to 17. Not all of
them were present with comparable amounts: consistent with the
EM observation, T7-like, followed by T4-like phages were the
major contributors. Other Podovirdae also made substantial con-
tributions: two additional T7-like phage groups (K1F and MmP1),
but also SP6-like, N4-like, P22-like and ε15-like genera of Podovir-
idae were identiﬁed. Beyond the T4 group, Myoviridae were also
prominently represented in the cocktail with rv5- and phAPEC8-
like phages, two recently described new Myovirus groups. Sipho-
viridae were also identiﬁed: distant relatives of the T1 phage
group and an unclassiﬁed group of Siphoviridae (“K1ind1”) were
observed. To our surprise, the second most prevalent “phage”
sequence after T7 was represented by ColProt1 obtained by de
novo assembly. This contig presents a 42 kb genome typical for
many phages, but has so few phage matches that its identity as a
new phage is for the moment only tentative. Since E. coli phages
are well investigated and now also well sequenced, one might
suspect a Proteus phage behind this contig. No Proteus phage
sequences are contained in public databases. In addition to these
relatively major contributing phages, several minor phage groups
were represented with much less sequence reads and low or nosequence conﬂicts suggesting that they were not intentionally
added to the cocktail, but induced at low frequency from pro-
phages contained in the hosts used for phage production.
Reference mapping and de novo assembly of the abundant
phages showed diversity within each phage group, indicating that
several related, but distinct phage isolates were contained in each
group. This observation raises the question as to how Microgen is
composing and propagating such a complex phage cocktail.
A complex phage cocktail is not only difﬁcult to produce and to
maintain at comparable quality and reproducibility, but it also
raises safety issues. We addressed the safety issue with two
approaches, but both were limited in scope. The ﬁrst was running
the phage sequences against a database of undesired genes, where
no matches of concern were found. However, here one might
argue that this approach excludes only known virulence factors
and undesirable genes, as the DUG database contains only genes
for which a function has been assigned. Phage genomes frequently
contain several new open reading frames (ORFs) for which func-
tion cannot be assigned that could code for undesirable functions
not yet identiﬁed. This is a limitation to the safety aspect of phage
genomes that should not be underestimated, even if the prob-
ability that these ORFs are “undesirable” is probably weak. There-
fore, we set up a small safety trial to explore the reaction of
healthy human volunteers to oral ingestion of the Microgen phage
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for adverse events associated with the consumption of this phage
cocktail. Here, one might argue that the number of enrolled
subjects was small and that rare side effects of the ColiProteus
phage cocktail cannot be excluded with the present data.
Finally, one might also ask why Microgen opted for complex
phage cocktails. That decision could reﬂect historical traditions of
Soviet phage therapy experience where new phages were regu-
larly added to the cocktail over decades to adapt it to the changing
epidemiology of the targeted pathogens without the old phages
being removed from the cocktail. The complex composition of the
phage cocktail might additionally reﬂect the difﬁculty to get a
good coverage of the pathogen. Most phages are not only species-
speciﬁc, but they infect only a limited scope of strains from a given
species. However, this coverage could theoretically also be
achieved with a cocktail of phages from a single phage group, as
we tested previously with a cocktail composed exclusively of
T4-like phages (Sarker et al., 2012). The Microgen approach (or
more generally, the Eastern European phage tradition) might also
represent a hedge betting strategy. Our knowledge about the
phage-bacterium interaction in the intestine is so fragmentary,
even with the workhorses of molecular biology research such as
phage T4 and E. coli, that we still do not know the factors
governing the in vivo phage infection process (Maura et al.,
2012a, 2012b; Brüssow, 2013). Microgen might have opted for
including different groups of phages into the cocktail hoping that
at least one group is efﬁciently replicating and lysing the E. coli
pathogen in the gut. That this consideration is not a moot point is
revealed by mouse experiments, where depending on the exact
experimental conditions either T7-like (Weiss et al., 2009) or
T4-like phages (Maura et al., 2012a, 2012b) are the better in vivo
replicators. We hope to will get some answers on these questions
and the virtues and drawbacks from different phage cocktail
strategies by a side-by-side comparison of our T4-like and the
Microgen ColiProteus phage cocktail in a controlled clinical trial in
children hospitalized with microbiologocally conﬁrmed E. coli
diarrhea.Material and methods
Phage cocktail
The commercial phage cocktail ColiProteus for the treatment of
E. coli diarrhea was purchased from Federal State Unitary Company
“Microgen Scientiﬁc Industrial Company for Immunobiological
Medicines” of the Ministry of Health and Social Department of
the Russian Federation (FSUC “SIC “Microgen”, MOHSD RF). Export
permits from Russia and import permits from Bangladesh were
obtained. Authorization to test this product in subjects from
Bangladesh was granted to the International Center for Diarrheal
Diseases Research (icddr,b) at Dhaka/Bangladesh in the clinical
protocol ICDDR, B #2008-062.
Microbiological tests
All laboratory methods (electron microscopy, fecal microbiota
proﬁling and high throughput sequencing of the phage DNA
isolated from the Microgen phage cocktail) were conducted as
described previously (Sarker et al., 2012).
Illumina sequencing and MetaGenomic analysis
Samples were processed in vitro to generate a DNA template
library of short inserts following a genomic shotgun protocol
(Fasteris SA, Switzerland). High-throughput DNA sequencing wasperformed using HiSeq 2000 technology (Illumina) to produce
100 bp paired-end reads. Sequencing quality of the reads was
veriﬁed using NGSqc Tool Kit (version 2.3) and sequences with
a quality scoreo20 were removed. In order to reduce the com-
plexity, reads with a 100% sequence identity were removed from
the total reads to generate a set of non-redundant (nr) reads.
This NR list was further reduced by removing reads that
shared 495% bp similarity. The closest homolog for these reads
was determined using blastx searches for the best hit against the
nr protein NCBI database. Reads with no hit were searched for
their closet homolog by blastn searches against the EMBL phage
database.
Taxonomical classiﬁcation and reference mapping
The resulting blastx ﬁle was loaded into the MetaGenomic
Analyzer (MEGAN) for taxonomical classiﬁcation (min support¼
100, min score¼68). A representative reference phage genome
from each taxonomical group identiﬁed in MEGAN was chosen
based on dot-plot alignments (mummer package version 3.06 with
default parameters, except that the minimum length of a maximal
exact match was set to 20; the results were displayed with
Mummerplot script with default parameters) and were used for
reference mapping using (NC_000866, NC_005066, NC_004928,
NC_005282, HQ829472, NC_011041, NC_007456, NC_001604,
NC_011085, HQ259105, NC_008152, NC_007603, GU196279) against
nr reads with SeqMan NGen software (version 3.1.0, DNAStar)
(identity 80%, mer size 19). Mappings that covered the majority of
the reference genome were further analyzed for coverage and
sequence divergences.
De novo assembly
All reads that were not mapped to the reference genomes were
compiled and de novo assembled with Seqman Ngen (identity 80%,
mer size 19, DNAStar). Contigs were investigated for their closest
homolog using blastn searches against the phage EMBL database
(e-value≤0.001) and contigs larger than 10 kb were manually
inspected. Results were visualized with Artemis Comparison Tool
(ACT, version 12).
Safety screening
The list of NR reads was mapped against an in-house Database
for Undesirable Genes (DUG), as described previously (Denou
et al., 2009). Genes were identiﬁed as potential hits when at least
one third of the subject gene was covered, and then these hits
were re-mapped using the full reads set. Manual inspection of
potential hits and homology searches were used to evaluate the
safety implications from DUG hits.
Safety test
Fifteen healthy human subjects from Nandipara, Bangladesh
were recruited for the safety study. Twenty mL of Microgen
ColiProteus preparation in 150 mL mineral water (Vittel, pH: 7.3,
258 mg bicarbonate/L) was given three times per day to ﬁve adults
over two days. For children the dose was reduced to 10 mL
Microgen phage in 75 mL of mineral water given three times per
day over two days (high dose). On E. coli indicator strain WG-5,
widely used in ecology studies, we measured a titer of 710 6 pfu
per mL. This titer is, however, only a minimal estimate since E. coli
phages not growing on WG-5 are not counted nor are Proteus
phages considered. The same subjects also received Microgen
phage at a ten-times lower dose (low phage) or placebo. Each
subject received all three treatments in random order. The study
S. McCallin et al. / Virology 443 (2013) 187–196 195design was identical to that reported previously (Sarker et al.,
2012). This type of design, known as repeated measures, uses
internal controls and has thus no formal control group, i.e. subjects
were studied when given placebo to represent internal subject-
speciﬁc controls. Each product was given over two days and effects
were observed over a week. Then a new treatment was given with
again a follow-up for a week, after which the third treatment was
given. This type of design presents some problems of analysis
should delayed effects occur which might be attributed to the
current product while it was in fact induced by the previous
product. The 15 study subjects were followed over three weeks for
adverse events by a panel of clinical, clinical chemistry and
hematological parameters described previously (Sarker et al.,
2012).Appendix A. Supporting information
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.virol.2013.05.022.References
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